Computational design and immunoinformatic validation of a multistage mRNA vaccine candidate against Mycobacterium tuberculosis

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Tuberculosis (TB),the biggest cause of death from any known infectious disease, has been a problem for the world's health system for many years. The only approved vaccine is BCG and now a number of vaccines are undergoing clinical trials. The newly recognised mRNA vaccines can provide a good alternative to the traditional vaccine. Therefore, the goal of this work is to use computational techniques to build a multi-stage tuberculosis mRNA vaccine. Nine multistage-expressing Mycobacterium tuberculosis (Mtb) proteins that have been linked to cell entry, pathogenesis, and dormancy regulon were used. Eighteen promiscuous, proinflammatory, non-toxic antigenic epitopes that bound to both MHC classes (I and II) were chosen from nine proteins. Co-translational structural components (5'm7G cap, UTRs, Kozak sequence, Poly A tail) were incorporated into the design of the mRNA vaccine, which was predicted to be extremely stable. Additionally, molecular docking reveals the vaccine candidate’s interaction with TLR2 and TLR4 immunological receptors by establishing a Leucine-Rich-Repeats (LRR) specific interface. Molecular dynamics (MD) simulations were also performed to evaluate the structural stability and dynamical behaviour of the vaccine candidate in complex with TLR2 and TLR4. Following the simulations, binding free energy calculations were conducted using the Molecular Mechanics/Poisson–Boltzmann Surface Area (MM/PBSA) method, which indicated stable thermodynamic binding of the vaccine candidate with both the receptors. Immune simulation tests using C-Immsim confirmed that the translated vaccine construct was immunogenic. Overall, it was anticipated that this multi-stage expressing mRNA vaccine would be highly immunogenic, stable, safe, and antigenic. Our method for creating an immunoinformatic-based mRNA vaccine can be an attractive tactic seems promising against tuberculosis, however, experimental validation needs to be carried out.

Article activity feed